Homepage / Technology / Goldman has a new favorite biotech because of potential Alzheimer's blockbuster
Former China internet regulator probed for suspected graft Cramer Remix: For investors scared of this market, it could be time to sell Cramer: Bitcoin and junk bonds are bubbles, but stocks aren't overvalued Marvell CEO on creating an internet of things infrastructure 'pure play' with Cavium acquisition Stocks are 'absolutely' overpriced, but it doesn't matter, says Empire Executions' Peter Costa Cramer: The market's 'era of good feelings' is lifting stocks despite bad news Asia set to open higher after US stocks reach record highs There's a '50/50' chance Meg Whitman will run for president in 2020, says Kevin O'Leary Uber hid a hack that exposed data of 57 million users and drivers for more than a year Trader who tried to bet against tech changes his tune Meg Whitman to leave role as CEO of Hewlett Packard Enterprise, shares tumble 6% Salesforce earnings: 39 cents a share vs expected EPS of 37 cents Electric trucks could sell faster than cars, but Tesla may be aiming at wrong end of the market Disney executive and Pixar co-founder John Lasseter takes leave of absence: Report JPMorgan has a new cybersecurity play, which it says could rally more than 20% JPMorgan reportedly getting into bitcoin futures trading even though Dimon believes it is a fraud Facebook allowed the buying of illegal housing ads months after it said it fixed the problem: Report Alphabet's Eric Schmidt: It can be 'very difficult' for Google to understand truth Forget FANG. These four tech stocks are outperforming this year, adding $600 billion in market cap The advertising-based internet is destroying society, tech pioneer says The case for reforming airport-slot allocation Bank of America sees end of bull market coming in 2018: Here's how it will happen Chinese micro-lenders are plunging on US exchanges after new regulations at home Wall Street analysts say AT&T will ‘prevail’ against DOJ over Time Warner These are the 10 fastest growing jobs in the U.S. US existing home sales rise 2 percent, beat expectations Read this before you buy a new 4K TV this Black Friday Suddenly bullish Goldman sees a big 2018 for stocks due to 'rational exuberance' Shoe retailer DSW stock plunges after company blames hurricanes for earnings miss Boeing shares to rally to new record on 'robust demand' for aircraft: Jefferies PayPal users can now send invoices over Facebook Messenger Amazon has suddenly become a big marketplace for selling genetic tests Apple iPhone X reportedly assembled with illegal student labor Stocks making the biggest moves premarket: LOW, HRL, MDT, DSW, CPB, T & more Dollar Tree profit beats estimates on higher customer traffic A cryptocurrency start-up disappeared with $375,000 from an ICO and nobody can find them Billionaire Mark Cuban says the 'big losers' of the move to block the AT&T-Time Warner merger are Facebook and Google Chip maker Micron, up almost 120% this year, has way more room to run, technician says Buckle up: Tesla could surge to $400 and then get cut in half in 2018, Morgan Stanley predicts This ride-hailing service will pick up your kids where school buses don't go China to fend off bubble risk with tighter property rules Broadcom eyes big changes for Qualcomm's patent practices Political turmoil is good for Angela Merkel, says analyst Iran President Rouhani declares end of Islamic State China's Tencent surpasses Facebook in valuation a day after breaking $500 billion barrier German liberal party member blames socialists for political turmoil, says there was 'zero' compromise Merkel's political future may hinge on one big gamble Tesla’s breakneck expansion speed could be a car crash Finance chiefs say bitcoin is 'real' but many think it's in a bubble right now European markets seen mostly lower on German political uncertainty UK's embattled government set for budget update — here's all you need to know More than $30 million worth of cryptocurrency was just stolen by hackers, company says Trump's latest move on North Korea is confusing experts US Treasury Dept. imposes sanctions on North Korea to curb military programs How personal shopping is giving retailers vital customer data India received a 'surprise' upgrade, but other ratings agencies may not be quick to follow SoftBank funding may spur Uber to re-think tough Southeast Asian market GOP plan will ultimately raise taxes on 50% of Americans, nonpartisan assessment says The FCC has plans to dismantle the rule protecting a neutral internet Cramer Remix: Forget the $450M painting, Intuitive Surgical is the da Vinci of stocks Cramer: The bulls are right about Ollie's Bargain Outlet, but the bears may have a point Airbnb lashes out at Marriott as clash between Silicon Valley and the hotel industry intensifies Cramer gets even more bullish on Netflix and Amazon after comments from Liberty Media's John Malone Cramer's take on Wall Street's top 15 'anointed' stocks for 2017 Asia set to open higher, following US gains overnight Colorado hits Uber with $8.9 million fine over shady drivers Eight women allege Charlie Rose sexually harassed them: Report Market is 'clearly near to a top,' says longtime bull Jeremy Siegel The start-up behind Denver's 200-mph Hyperloop system: 'We love regulation' Tesla has dropped more than 20 percent from September's all-time high The debt time bomb that keeps growing and now equals nearly half of US GDP Square will generate $30 million in annual sales from bitcoin in 2 years, Credit Suisse predicts It's not the economy, stupid. What retail advisors are really worried about this holiday season Vivendi declines to try to take over Ubisoft, for now FanDuel CEO and co-founder Nigel Eccles is leaving to start an eSports company Bitcoin is working well for some big-ticket purchases despite its volatility Ex-Facebook privacy manager says company cares more about data collection than protecting users For its 10th anniversary, Jeff Bezos posted 'before' and 'after' photos of Kindle on Instagram America’s culture wars are spreading to hotels Wall Street is betting against Tinder. Here's why the company's going to succeed Standpoint's Ronnie Moas predicts bitcoin will surge another 70% Apple's new visitor center is now open to the public and dishing out some exclusive swag Salesforce CEO Marc Benioff: 'There's no finish line when it comes to equality' If the US had this H1-B fight in the past, we'd never have gotten Elon Musk, says Roger McNamee The stock market is 'dancing on the rim of a volcano,' warns investment bank eBay leans on AI to help you find the right gift for the holiday season How to find out what Google knows about you and limit the data it collects Merkel says she would prefer new elections to minority government Major AI funding boost in UK aims to fuel driverless car revolution Amazon launches a cloud service for US intelligence agencies Gamers are overreacting to EA's ‘Star Wars’ controversy, publishers should raise prices: Analyst US credit access, financial fragility improve: Fed survey Elon Musk teases flying cars: ‘Rocket tech applied to a car opens up revolutionary possibilities’ Amazon shares to keep rallying as company uses massive spending to deepen its 'moat': Analyst Uber set to buy self-driving cars from Volvo, rivaling Lyft's fleet GM shares upgraded because of automaker's 'advanced' autonomous technology Number of DDoS attack attempts increasing, research shows Victoria's Secret fashion show hits Shanghai without Katy Perry and supermodel Gigi Hadid Jack Bogle’s 5 bold investment predictions for 2018 and beyond EU's preference is ambitious trade deal with UK, Barnier says

Technology

Goldman has a new favorite biotech because of potential Alzheimer's blockbuster

Goldman Sachs added Biogen to its Americas Conviction List, highlighting the biotech’s lead pipeline Alzheimer’s drug as possibly one of the first to successfully prevent or slow the progression of the disease.

“Biogen has a broad Alzheimer’s disease portfolio, which, if successful, would allow it to access a greenfield, blockbuster market opportunity,” wrote Goldman analyst Terence Flynn, Ph.D. “It is difficult to overstate the growing societal burden of Alzheimer’s disease … By 2050, one new case of Alzheimer’s disease is expected to develop every 33 seconds in the United States.”

Cambridge-based Biogen focuses on discovering and developing therapies for neurological and hematologic disorders including multiple sclerosis and hemophilia. Through a partnership with Eisai, the two companies have two Alzheimer’s drugs in late-stage development, both of which could be huge money generators.

Goldman projects that one of the two drugs, known as Aducanumab, could reach peak sales of $12 billion.

The analyst has a $338 price target on Biogen, representing 17 percent upside from Tuesday’s close. The shares rose 1.4 percent in premarket trading Wednesday after Goldman’s call.

Biogen is also a key player in treatment of multiple sclerosis, handling 38 percent of all MS patients globally. With more and more competitors entering the MS market, Biogen has started to feel pressure on some of its established drugs.

“MS is a mature market and competition has been increasing. But while generics and other new entrants could capture share, we don’t expect wholesale ‘re-pricing’ of the category,” continued Flynn.

In all, Goldman Sachs not only sees room for drug catalysts, but additional business development could provide Biogen with free cash.

“Our firepower analysis suggests $14 billion in capacity, which is above what management discussed on the 2Q call regarding the maximum size deal it could pursue,” wrote Flynn.

“Hence, in addition to potential business development deals, we believe the company could more aggressively repurchase shares.”

Source: Tech CNBC
Goldman has a new favorite biotech because of potential Alzheimer's blockbuster

Comments are closed.